| A. | Cytogen      and Inpharma entered into a Product License and Assignment Agreement dated      as of October 11, 2006, as amended as of August 30, 2007 (the “License      Agreement”). |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B. | Cytogen      and Inpharma wish to amend the terms of the License Agreement as set forth      below in accordance with Section 9.05 of the License      Agreement. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1. | Any      defined terms utilized herein and not otherwise defined herein shall have      the meaning ascribed thereto in the License  Agreement. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | Section      2.04(a) of the License Agreement is hereby amended in its entirety as      follows: |
|--------|----|--------------------------------------------------------------------------------------------------|

|   | 3. | Section      3.04 of the License Agreement is hereby amended in its entirety as      follows: |
|--------|----|-----------------------------------------------------------------------------------------------|

----

----

----

|   | 4. | Section      8.01 of the License Agreement is hereby amended in its entirety as      follows: |
|--------|----|-----------------------------------------------------------------------------------------------|

|   | 5. | Section      8.02 of the License Agreement is hereby amended in its entirety as      follows: |
|--------|----|-----------------------------------------------------------------------------------------------|

----

|   | 6. | Section      8.03 of the License Agreement is hereby amended in its entirety as      follows: |
|--------|----|-----------------------------------------------------------------------------------------------|

|   | 7. | Section      8.04(a) of the License Agreement is hereby amended in its entirety as      follows: |
|--------|----|--------------------------------------------------------------------------------------------------|

|   | 8. | Insert      new Section 8.04(c): |
|--------|----|----------------------------------|

----

|   | “Any      sublicense shall survive termination of this Agreement if the sublicensee      complies with the following: (i) if Cytogen has exercised the Option for      Europe only, or Asia only, and has sublicensed its rights to the Product      in such Option Territory to a sublicensee, such sublicense shall survive      if Cytogen has paid the exercise price for the applicable Option set forth      in Section 3.04, and the sublicensee shall assume in writing any      outstanding obligations of Cytogen pursuant to this Agreement with respect      to the applicable Option Territory, including without limitation the      obligation to pay any amounts due to Inpharma under Section 3.04 of this      Agreement and remaining unpaid; (ii) if Cytogen has exercised the Options      for both Europe and Asia and Cytogen has sublicensed its rights for Europe      and/or Asia to one or more sublicensees, such sublicense(s) shall survive      if Cytogen has made the initial payment referenced in Section      3.04(g)(i)(1) and such sublicensee(s) shall assume in writing any other      outstanding obligations of Cytogen pursuant to this Agreement with respect      to Europe and/or Asia, as applicable; (iii) if Cytogen has exercised the      Options for both Europe and Asia and Cytogen has sublicensed its rights      for the United States to a sublicensee, such sublicense shall survive if      Cytogen has made the payments referenced in Section 3.04(g)(i)(2) or if      such sublicensee shall assume in writing the obligation to make any      remaining payments referenced in Section 3.04(g)(i)(2) and any other      outstanding obligations of Cytogen pursuant to this Agreement with respect      to the United States; (iv) if Cytogen has sublicensed its rights to the      Product in the United States and Cytogen has not exercised both Options,      Cytogen’s sublicense shall survive if the sublicensee shall assume in      writing any outstanding obligations of Cytogen applicable to the Initial      Territory, including without limitation the obligation to pay any amounts      due to Inpharma under Section 3.02 and 3.03  remaining unpaid;      and (v) if both Options have been exercised and Cytogen has sublicensed      its rights for Europe and Asia to a single sublicensee and such sublicense      survives termination in accordance with clause (ii) of this Section 8.03,      Cytogen’s sublicensee for Europe and Asia shall have the option (unless      Cytogen has separately sublicensed the rights to the Product for the      United States to a third party and such sublicense survives such      termination) to expand its license to include the United States on the      terms and conditions (including without limitation the obligation to pay      to Inpharma any remaining payments under Section 3.04(g)(i)(2)) set forth      in this Agreement.” |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 9. | Except      as expressly provided in this Amendment, all other terms, conditions and      provisions of the License Agreement shall continue in full force and      effect as provided therein. Any reference to the License Agreement in any      instrument or agreement shall mean and include the License Agreement as      amended by this Amendment.  In the event of any conflict between      the terms of the License Agreement and the terms of this Amendment, the      terms of this Amendment shall govern and  control. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 10. | The      License Agreement and this Amendment constitute the entire understanding      between the parties, except as expressly set forth herein, and supersede      any contracts, agreements or understanding (oral or written) of the      parties with respect to the subject matter hereof.  No term of      this Amendment may be amended except upon written agreement of the      parties. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 11. | This      Amendment may be executed by facsimile or “.pdf” file and in one or more      counterparts, each of which will be deemed an original but all of which      together will constitute one and the same  instrument. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----